|
|
|
|
 |
|
SENSEX
|
 |
-456.53
|
-0.63%
|
|
71569.62
|
|
|
|
NIFTY
|
 |
-141.60
|
-0.65%
|
|
21569.20
|
|
|
|
Nasdaq
|
 |
13.77
|
0.09%
|
|
14524.07
|
|
|
|
Nikkei 225
|
 |
89.13
|
0.27%
|
|
33377.42
|
|
|
|
FTSE 100
|
 |
-33.50
|
-0.43%
|
|
7689.60
|
|
|
 |
|
|
|
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Industry : Pharmaceuticals & Drugs |
House : Sequent |
|
BSE Code |
512529
|
|
ISIN Demat |
INE807F01027
|
|
Book Value (Rs) |
42.63
|
|
|
NSE Code |
SEQUENT
|
|
Dividend Yield % |
0.00
|
|
Market Cap (Rs) |
33436.56
|
|
|
TTM PE(x) |
0.00
|
|
TTM EPS(Rs) |
-0.42
|
|
Face Value(Rs.) |
2
|
|
|
|
|
|
|
|
|
|
|
|
Incorporation Year
|
28-06 1985
|
|
Registered Office
|
301, ' Dosti Pinnacle',3rd Floor, Plot No. E7,Road No. 22, Wagle Indl. Estate, Thane, Maharashtra-400604 .
|
|
ISINNO
|
INE807F01027
|
|
Phone
|
022 4111 4777
|
|
E-mail
|
investorrelations@sequent.in |
|
URL
|
www.sequent.in |
|
Industry
|
Pharmaceuticals & Drugs
|
|
Chairman
|
Kamal K Sharma
|
|
Managing Director
|
Rajaram Narayanan
|
|
Company Secretary
|
Krunal Shah
|
|
Listing
|
BSE,NSE
|
|
|
|
|
|
|
|
|
|
|
|